Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced   breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving   talazoparib (TALA) vs physician's choice chemotherapy (PCT) in the   EMBRACA trial: A focus on subgroups with/without visceral disease

Title:: Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/without visceral disease
Document type:: Meeting Abstract
Author(s):: Ettl, J.; Quek, R. G. W.; Bhattacharyya, H.; Rugo, H. S.; Hurvitz, S. A.; Goncalves, A.
Journal title abbreviation:: Ann Oncol
Year:: 2019
Journal volume:: 30 Suppl 5
Pages contribution:: 129-+
Print-ISSN:: 0923-7534
TUM Institution:: Frauenklinik und Poliklinik
BibTeX

Occurrences: